DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
6.22
-0.10 (-1.58%)
At close: Apr 28, 2026, 4:00 PM EDT
6.22
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:10 PM EDT
DiaMedica Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
35
Market Cap
335.15M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bicycle Therapeutics | 72.59M |
| Surrozen | 3.48M |
| Compass Therapeutics | 850.00K |
| vTv Therapeutics | 17.00K |
| Inhibikase Therapeutics | 1.00 |
DMAC News
- 12 days ago - DiaMedica Therapeutics Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators - Transcripts
- 4 weeks ago - DiaMedica Therapeutics Earnings Call Transcript: Q4 2025 - Transcripts
- 4 weeks ago - DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights - Business Wire
- 4 weeks ago - Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings - Benzinga
- 5 weeks ago - DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026 - Business Wire
- 7 weeks ago - DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia - Business Wire
- 2 months ago - DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences - Business Wire
- 3 months ago - DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire